Advertisement

Topics

CHRIS BEAVER JOINS PHARMANET AS DIRECTOR, IMMUNOCHEMISTRY SERVICES

13:08 EST 29 Nov 2010 | BioPortfolio

Princeton, NJ – November 29, 2010 – PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announces that Chris Beaver, PhD has joined the Company as Director, Immunochemistry Services. Dr. Beaver is responsible for leading the immunochemistry team within the Company’s bioanalytical laboratories and expanding its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.

“We are very excited to have Chris joining us,” said Dr. Richard LeLacheur, Vice President. “Chris brings to PharmaNet a combination of CRO leadership experience and technical expertise in large molecule bioanalysis that enhances our ability to support the drug development strategies of our clients. He is a valuable addition to our bioanalytical team.”

Dr. Beaver’s appointment strengthens PharmaNet’s offerings in large molecule bioanalytical services to support the growing interest in biologics and biosimilars within the pharmaceutical industry. PharmaNet has two GLP-compliant bioanalytical laboratories which are located in Princeton, New Jersey and Quebec City, Canada.

Previously, Dr. Beaver served as Scientific Director of Ligand Binding/Cell Based Assays at another clinical research organization with macromolecule bioanalysis operations. He completed his Ph.D. in Neuroscience at Dalhousie University in Halifax, Canada, followed by post-doctoral training at Yale University. Dr. Beaver is published in multiple scientific publications, including Drug Discovery World and Nature Neuroscience.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.

###

For Immediate Release Contact: Anne-Marie Hess
Date: November 29, 2010 Phone: (609) 951-6842
E-mail: ahess@pharmanet.com

NEXT ARTICLE

More From BioPortfolio on "CHRIS BEAVER JOINS PHARMANET AS DIRECTOR, IMMUNOCHEMISTRY SERVICES"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...